OLYMPUS

Your Vision, Our Future

EVIS EXERA III

13637

SEE AND TREAT

Endoscopic Intervention with Olympus

Interventional endoscopy has undergone rapid development. Many patients who would have required surgery not long ago can be easily treated via endoscopic therapy now.

EMR, ESD, POEM, and stenting are only a few chapters of a success story that gastroenterologists like you are writing every day. With innovative endoscopic technologies – such as Dual Focus and NBI, coupled with a range of perfectly matched endotherapy instruments – Olympus provides you with the tools you need to provide targeted and effective treatment.

Discover more today at www.olympus-europa.com.



Figures: Courtesy of the Asklepios Klinik in Hamburg Barmbek.

OLYMPUS EUROPA SE & CO. KG
Postbox 10 49 08, 20034 Hamburg, Germany | Phone: +49 40 23773-0 | www.olympus-europa.com

The International Endoscopy Forum

ENDO CLUB NORD

November 6 and 7, 2015

Congress Center Hamburg

President: Thomas Rösch

Friedrich Hagenmüller
Siegbert Faiss

www.endoclubnord.com

1. Ell C. et al. American Journal of Gastroenterology 2008; 103(4):883-893.

MOVIPREP®/MOVIPREP® ORANGE, Pulver zur Herstellung einer Lösung zum Einnehmen
Zusammensetzung: Beutel A enthält: Macrogol 3350 100 g, Natriumsulfat 7,5 g, Natriumchlorid 2,691 g, Kaliumchlorid 1,015 g; Beutel B enthält: Ascorbinsäure 4,7 g, Natriumascorbat 5,9 g. Hilfsstoffe MOVIPREP®: Aspartam, Acesulfam-Kalium, Zitronenaroma. Hilfsstoffe MOVIPREP® ORANGE: Aspartam, Acesulfam-Kalium, Orangenaroma. **Anwendungsgebiete:** Zur Darmvorbereitung vor klinischen Maßnahmen, die einen sauberen Darm erfordern, z.B. endoskopische oder radiologische Untersuchungen des Darms. **Gegenanzeigen**: Gastrointestinale Obstruktion oder Perforation, Störungen der Magenentleerung, Ileus, Phenylketonurie, Glukose-6-Phosphatdehydrogenase-Mangel, Überempfindlichkeit gegen die Wirkstoffe oder die sonstigen Bestandteile, toxisches Megakolon als Komplikation schwerer entzündlicher Darmerkrankungen. MOVIPREP®/MOVIPREP® ORANGE darf nicht bei bewusstlosen Patienten angewendet werden. **Nebenwirkungen:** Sehr häufig: Abdominalschmerz, Übelkeit, abdominale Aufblähung, Analreizungen, Unwohlsein. Häufig: Schlafstörungen, Schwindel, Kopfschmerzen, Erbrechen, Dyspepsie, Rigor, Durst, Hunger. Gelegentlich: Dysphagie, Leberfunktionstests anormal, Unbehagen. Nicht bekannt: Anaphylaxie, Krampfanfälle im Rahmen einer ausgeprägten Hyponatriämie, vorübergehender Anstieg des Blutdrucks, Flatulenz, Brechreiz, Pruritus, Urticaria, Hautausschlag, Elektrolytverschiebungen einschließlich Bikarbonatkonzentration im Blut vermindert, Hyper- und Hypocalciämie, Phosphatkonzentration im Blut vermindert, Hypokaliämie und Hyponatriämie (die beiden letztgenannten Störungen treten häufiger bei Patienten auf, die gleichzeitig Medikamente einnehmen, die einen Einfluss auf die Niere haben, wie z.B. ACE-Inhibitoren und Diuretika) sowie Änderungen der Chloridkonzentration im Blut. **Handelsformen:** Eine Anwendung besteht aus 2 Btl. A und 2 Btl. B. Packungsgrößen von 1 (N 1), 10, 40, 80, 160 und 320 Packungen einer einzelnen Anwendung. Klinikpackung mit 40 einzelnen Anwendungen. Apothekenpflichtig. Stand 07/2012

NORGINE

MOVIPREP, NORGINE and the sail logo are registered trademarks of the Norgine Group of companies.

ENDOCLUBNORD 2015

Scientific Chairman and responsible for the editorial content:

Prof. Dr. Thomas Rösch
Universitätsklinikum
Hamburg-Eppendorf

Download Program

Design and Layout

COCSMEDIA

Rosenheimer Str. 145c · 81671 Munich, Germany
www.cocs-media.de

COCS media does not guarantee the correctness of information.

Distribution supported by Olympus Europa Holding GmbH.

CitraFleet®
Natriumpicosulfat + Magnesiumcitrat



Zur Darmreinigung vor Koloskopien oder Röntgenuntersuchungen

Für eine gründliche Entleerung und Reinigung[1]

- Duales Wirkprinzip durch zwei Wirkstoffe[1]
- Hohe Patientenverträglichkeit[2]
- Schmeckt angenehm nach Zitrone[3]

[1] Fachinformation CitraFleet® Stand 12/2010
[2] Ciáurriz A, et al. Calidad de la colonoscopia: efectividad y tolerancia de tres regimenes de limpieza. Poster presented at Semana de las Enfermedades Digestivas (SED) 11-14 de Junio, 2011. Sevilla, Spain.
[3] Schirin-Sokhan R., Trautwein C., MMW Fortschritte der Medizin Originalien 2009; 151(1): 34-38

CitraFleet® Pulver zur Herstellung einer Lösung zum Einnehmen in einem Beutel. Wirkstoffe: Natriumpicosulfat, leichtes Magnesiumoxid, wasserfreie Citronensäure. **Zusammensetzung:** 1 Beutel mit 15,08 g Pulver enth. 10,0 mg Natriumpicosulfat, 3,5 g leichtes Magnesiumoxid und 10,97 g wasserfreie Citronensäure. Sonst. Bestandt.: Kaliumhydrogencarbonat, Saccharin-Natrium, Zitronenaroma (Zitronenaroma, Maltodextrin, RRR-α-Tocopherol E 307). **Anwendungsgebiete:** für Erwachsene ab 18 Jahren: zur Darmreinigung vor jeder diagnostischen Untersuchung, die nur bei einem gut gereinigten Darm sinnvoll durchgeführt werden kann (z.B. Koloskopie, Röntgen). **Gegenanzeigen:** Überempf. gg. Bestandt., dekomp. Herzinsuff., schwere Dehydrat., Hypermagnesiemie, Magenretention, Ulzerat. GIT, tox. Colitis, tox. Megacolon, Ileus, Übelkeit, Erbrechen, Aszitis, Appendizitis, Obstr./Perfor. GIT, Rhabdomyolyse, aktive Entzündung (Morbus Crohn, Colitis ulcerosa), eingeschr. Nierenfunkt. **Warnhinweise:** enthält 5 mmol Kalium. **Nebenwirkungen:** sehr häufig: Bauchschm. häufig: Schlafst., Kopfschm., Mundtrock., Übelkeit, Bläbauch, Analbeschw., Proktalgie, Durstgef., Müdigk., gelegentlich: Schwindel, orthostat. Hypot., Erbrechen, Stuhlinkont., Häufigk. n. bekannt: Anaphylaktoide Reakt., Überempf., Hyponatriämie, Epilepsie, Grand-mal-Anfall, Konvuls., Verwirrtheitszust., Durchfall, Flatulenz, Hautausschl., Urtikaria, Pruritus, Purpura, Schmerzen. **Apothekenpflichtig. Stand:** April 2012. **Zulassungsinhaber:** Laboratorios Casen-Fleet S.L.U., Autovía de Logroño Km 13,300, 50180 UTEBO, Zaragoza, Spanien. **Mitvertrieb:** Recordati Pharma GmbH, Eberhard-Finckh-Str. 55, 89075 Ulm.

RECORDATI PHARMA GROUP

PD Dr. Siegbert Faiss Prof. Dr. Thomas Rösch Prof. Dr. Friedrich Hagenmüller

Welcome to the 23rd ENDOCLUBNORD!

Dear guests and endoscopy experts,

We look forward to welcoming you to the 23rd ENDOCLUBNORD in Hamburg on November 6 and 7, 2015. Again this year, we will be demonstrating the latest developments in flexible gastroenterological endoscopy. This ENDOCLUBNORD will focus in particular on interfaces between endoscopy and histopathology as well as minimally invasive surgery. You will be able to see many exciting live cases, followed by case discussions on Saturday. For the first time, Friday evening will be finished with high-class workshops with possibilities to get direct answers to all your questions.

Gastrointestinal pathology has always been our gold standard essentially backing up diagnostic endoscopy. The exciting development of endoscopic imaging, resulting in super-high resolutions and details, allows us to view structures that almost seem to match tissue diagnosis. We also have a long and fruitful relationship with minimally invasive surgery, another area where see continuous progress.We wish to work on and discuss all these questions with you.

Come to Hamburg, Germany's premiere location for endoscopy, on November 6 and 7! We look forward to seeing you there!

Siegbert Faiss
Asklepios Klinik Barmbek

Thomas Rösch
President 2015
Universitätsklinikum Hamburg-Eppendorf

Friedrich Hagenmüller
Asklepios Klinik Altona

9.00 – 9.15 a.m. **Opening and Introduction**
President: Thomas Rösch, Hamburg
Honorary President: Manfred Stolte, Kulmbach
Honorary Member: Kazuhiro Saito, Tokyo, Japan

9.15 – 10.10 a.m. **Endoscopy live, Part 1**
Live Video Broadcast from the three Hospitals: Asklepios Klinik Altona, Asklepios Klinik Barmbek and Universitätsklinikum Hamburg-Eppendorf

10.10 – 10.30 a.m. **IBD – Update 2015: endoscopy, diagnostics, therapy**
Axel Dignaß, Frankfurt
AbbVie Lecture

10.30 – 11.15 a.m. **Endoscopy live, Part 2**

11.15 – 11.45 a.m. Coffee Break in the Industry Exhibition

11.45 – 12.40 p.m. **Endoscopy live, Part 3**

12.40 – 01.00 p.m. **Liver cirrhosis – a malignant disease**
Ansgar Lohse, Hamburg
Norgine Lecture

01.00 – 01.50 p.m. Lunch Break in the Industry Exhibition

01.50 – 02.50 p.m. **Endoscopy live, Part 4**

02.50 – 03.10 p.m. **New specific mechanisms in IBD therapy – perspectives**
Britta Siegmund, Berlin
Takeda Lecture

03.10 – 04.00 p.m. **Endoscopy live, Part 5**

04.00 – 04.20 p.m. Coffee Break in the Industry Exhibition

04.20 – 05.00 p.m. **Endoscopy live, Part 6**

FRIDAY, NOVEMBER 6, 2015

05.15 – 06.30 p.m. **Workshops und discussions - NEW -**
Registration required, no extra charge.

Seminar für Pflege- und Assistenzpersonal
Therapeutische Endoskopie
Leitung: Hans-Dieter Allescher
Teilnehmer: Ute Pfeifer, Rita Hieber, Martin Mangold, Kollegen aus den drei Hamburger Kliniken

Workshop 1
Advanced polypectomy
Chair: Horst Neuhaus
Discussants: Dirk Hartmann, Kenneth Binmoeller, Helmut Messmann

Workshop 2
ERCP – Cannulation, precut and sphincterotomy
Chair: Paul Fockens
Discussants: Jacques Devière, Alexander Meining, Stefan Seewald

Workshop 3
Early tumors in esophagus and stomach
Chair: Friedrich Hagenmüller
Discussants: Oliver Pech, Uwe Seitz, Naohisa Yahagi

Workshop 4
Overview on Novel Pancreatibiliary Interventions
Together with SADE und National Societies Poland, Czech Republic and Hungary
Chair: Thomas Rösch
Discussants: Lars Aabakken, Jaroslaw Regula, Julius Spicak, István Rácz

9.00 – 10.30 a.m.	**Friday's Highlights Part 1** Histology, Evidence and Discussion *Andrea Tannapfel, Bochum* *Thomas Rösch, Hamburg* *Friedrich Hagenmüller, Hamburg* *Siegbert Faiss, Hamburg*
10.30 – 11.00 a.m.	Coffee Break and visit in the Industry Exhibition
11.00 – 11.45 a.m.	**Pathology and Endoscopy: Scenes from a Marriage** Barrett esophagus, IBD surveillance, resect and discard strategy, serrated adenomas *Andrea Tannapfel, Bochum* *Gustavo Baretton, Dresden* *Michael Vieth, Bayreuth* *Thomas Rösch, Hamburg* *Friedrich Hagenmüller, Hamburg* *Siegbert Faiss, Hamburg*
11.45 – 12.30 p.m.	**Friday's Highlights Part 2** Histology, Evidence and Discussion *Andrea Tannapfel, Bochum* *Thomas Rösch, Hamburg* *Friedrich Hagenmüller, Hamburg* *Siegbert Faiss, Hamburg*
12.30 – 01.00 p.m.	**The most interesting cases from 2014 – follow-up**
01.00 – 01.15 p.m.	Closing Remarks and Invitation to the 24. ENDOCLUBNORD November 4 and 5, 2016

HONORARY PRESIDENT

Prof. Dr. Dr. Manfred Stolte
Kulmbach, Germany

HONORARY MEMBER

Kazuhiro Saito
Tokyo, Japan

FOUNDING PRESIDENT

Prof. Dr. Nib Soehendra
Hamburg, Germany

Prof. Dr. Lars Aabakken
Rikshospitalet University Hospital

Oslo, Norway

Prof. Dr. Hans-Dieter Allescher
Klinikum Garmisch-Partenkirchen

Garmisch-Partenkirchen, Germany

Dr. Jens Aschenbeck
Praxis

Berlin, Germany

Prof. Dr. Gustavo B. Baretton
Universitätsklinikum Carl Gustav Carus

Dresden, Germany

Dr. Julia Bertolini
MVZ Hanse Histologikum GmbH

Hamburg, Germany

Prof. Dr. Kenneth Binmoeller
California Pacific Medical Center

San Francisco, California, USA

Prof. Dr. Jacques Devière
Universite Libre des Bruxelles Hospital Erasme

Brussels, Belgium

Prof. Dr. Axel Dignaß
Agaplesion Markus Krankenhaus

Frankfurt, Germany

Targeted mesalazine for
mild ileocaecal Crohn's disease



- **Targeted release**
  in the terminal ileum and colon ascendens
- **High local luminal concentrations**
  due to accelerated release
- **Proven efficacy**
  in mildly active ileocaecal Crohn's disease[1]

Salofalk® *Tablets*

Mesalazine with Crohn's galenic

Salofalk® Tablets are not approved for Crohn's disease in all countries. Please refer to your local SPC.

* Crohn's Disease Activity Index (CDAI) ≤ 300.
1 Tromm et al., Gastroenterology. 2011;140:425–34

Salofalk® Granules 500mg/1000mg/1.5g/3g; Salofalk® 250mg/500mg Gastro-resistant tablets, Salofalk® 250mg/500mg/1g Suppositories, Salofalk® 2g/30ml and 4g/60ml Enemas; Salofalk® 1g Rectal Foam. Active ingredient: mesalazine (5-aminosalicylic acid). **Composition:** 1 sachet of Salofalk® granules 500mg/1000mg/1.5g/3g contains: active ingredient: 500 mg/1000 mg/1.5 g/3 g mesalazine. Other ingredients: aspartame (E951), carmellose sodium, citric acid, silica colloidal anhydrous, hypromellose, magnesium stearate, methacrylic acid-methyl methacrylate copolymer (1:1) (Eudragit L 100), methylcellulose, cellulose microcrystalline, polyacrylate dispersion 40% (Eudragit NE 40 D containing 2% Nonoxynol 100), povidone K25, simeticone, sorbic acid, talc, titanium dioxide (E171), triethyl citrate, vanilla custard flavouring (containing propylene glycol). 1 tablet of Salofalk® 250mg/500mg contains: active ingredient: 250 mg/500 mg mesalazine. Other ingredients: Calcium stearate, basic butylated methacrylate copolymer (=Eudragit E), methacrylic acid methyl methacrylate copolymer (1:1) (=Eudragit L), glycine, silica colloidal anhydrous, hypromellose, macrogol 6000, cellulose microcrystalline, sodium carbonate anhydrous, povidone K25, talc. Colouring agents: titanium dioxide (E171), iron oxide hydrate (E172), additionally Salofalk® 500mg tablets: croscarmellose sodium. 1 Salofalk® 250mg/500mg/1g suppository contains: active ingredient: 250 mg/500 mg/ 1 g mesalazine. Other ingredients: hard fat; additionally Salofalk® 500mg suppositories: docusate sodium, cetyl alcohol. 1 enema of Salofalk® 2g/30ml or 4g/60ml contains: active ingredient: 2 g or 4 g mesalazine. Other ingredients: sodium benzoate (E211), potassium metabisulphite (E224), potassium acetate, carbomer 947P, sodium edetate, xanthan gum, purified water. Note: Salofalk® enemas contain sodium benzoate and potassium metabisulphite. See patient information leaflet. Salofalk® 1g Rectal Foam: 1 actuation contains: active ingredient: 1 g mesalazine. Other ingredients: sodium metabisulphite (E223), cetostearyl alcohol, polysorbate 60, sodium edetate, propylene glycol. Propellants: propane, n-butane, isobutane. Note: Salofalk® 1g Rectal Foam contains sodium metabisulfite (E223), propylene glycol and cetostearyl alcohol. See patient information leaflet. **Indications:** Salofalk® granules 500mg/1000mg/1.5g/3g: acute treatment and prevention of recurrence of ulcerative colitis. Salofalk® 250mg/500mg tablets: acute treatment and prevention of recurrence of ulcerative colitis. Acute treatment of Crohn's disease. Salofalk® 250mg/500mg/1g suppositories: acute treatment of (1g: mild to moderate) ulcerative colitis confined to the rectum. Additionally Salofalk® 250mg suppositories: prevention of recurrence of ulcerative colitis. Salofalk® 2g/30ml enemas: acute treatment of mild to moderate ulcerative colitis, localised in the rectum and sigmoid colon. Salofalk® 4g/60ml enemas: acute treatment of ulcerative colitis. Salofalk® 1g Rectal Foam: Treatment of active, mild ulcerative colitis of the sigmoid colon and rectum. **Contraindications:** known hypersensitivity to salicylates or any of the excipients, severe impairment of hepatic or renal function. Pregnancy and lactation: risk-benefit ratio. Additionally for Salofalk® Enemas and Rectal Foam: not to be used in case of sensitive patients (especially for known asthmatics or allergic anamnesis) due to the content of metabisulphite or sodium benzoate. **Side effects:** headaches, dizziness, peripheral neuropathy, abdominal pain, diarrhea, flatulence, nausea, vomiting, impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency. Hypersensitivity reactions such as allergic exanthema, drug fever, pancolitis, lupus erythematosus syndrome, allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis), peri- and myocarditis, acute pancreatitis, myalgia, arthralgia, altered blood counts (aplastic anemia, agranulocytosis, pancytopenia, neutropenia, leucopenia, thrombocytopenia), changes in liver function parameters (increase in transaminases and parameters of cholestasis), hepatitis, cholestatic hepatitis, alopecia, oligospermia (reversible). Additionally for Salofalk® 1g Rectal Foam: abdominal distension, anal discomfort, application site irritation, painful rectal tenesmus. Salofalk® 1g Supp.: constipation. **Interactions and dosage:** see patient information leaflet. Available on prescription only. Date of information: 11/2012

DR. FALK PHARMA GmbH
Leinenweberstr. 5
79108 Freiburg
Germany
www.drfalkpharma.com

Dr. Bernd Feyerabend
MVZ Hanse Histologikum GmbH
Hamburg, Germany

Prof. Dr. Paul Fockens
Academic Medical Center
University of Amsterdam
Amsterdam, The Netherlands

PD Dr. Dirk Hartmann
Sana Klinikum Lichtenberg
Oskar-Ziethen-Krankenhaus
Berlin, Germany

Rita Hieber
Klinikum Augsburg
Augsburg, Germany

Prof. Dr. Stephan Hollerbach
Allgemeines Krankenhaus Celle
Celle, Germany

Prof. Dr. Ansgar Lohse
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany

Martin Mangold
Klinikum Garmisch-Partenkirchen
Garmisch-Partenkirchen, Germany

PD Dr. Oliver Mann
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany

Prof. Dr. Alexander Meining
Universitätsklinikum Ulm
Ulm, Germany

Prof. Dr. Helmut Messmann
Klinikum Augsburg
Augsburg, Germany

Dr. Gero Moog
Gastroenterologische Fachpraxis
Kassel, Germany

Prof. Dr. Horst Neuhaus
Evangelisches Krankenhaus Düsseldorf
Düsseldorf, Germany

Recently approved in the EU!

A new therapy option to treat Short Bowel Syndrome

DGEM S3-GUIDELINES RECOMMENDED

Optimizes the absorptive capacity of the intestine[1,2]



Biopsy of a study participant

References:

1. Jeppesen et al., Gut 2005;54:1224–1231

2. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM323506.pdf



All details and the prescribing information can be found at:

www.npsp.de/arzneimittel

NPS Pharma Germany GmbH · The Squaire 12,
Am Flughafen · 60549 Frankfurt/Main
Tel: 069 959 325 208 · E-Mail: info@npsp.de

NPS Pharma™
The Nexus of Patients and Science™

Dr. Gabriele Niemann
HELIOS Klinikum
Emil von Behring

Berlin, Germany

Dr. Michael Oelckers
Albertinen-Krankenhaus

Hamburg, Germany

Prof. Dr. Karl-Jürgen Oldhafer
Asklepios Klinik Barmbek

Hamburg, Germany

PD Dr. Oliver Pech
Krankenhaus Barmherzige Brüder Regensburg

Regensburg, Germany

Dr. Ute Pfeifer
Evangelisches Krankenhaus Düsseldorf

Düsseldorf, Germany

István Rácz
Petz Aladar County and Teaching Hospital

Győr, Hungary

Prof. Dr. Jaroslaw Regula
Medical Center for Postgraduate Education and Institute of Oncology
Warsaw, Poland

Prof. Dr. Hans-Joachim Schulz
Sana Klinikum Lichtenberg

Berlin, Germany

Prof. Dr. Wolfgang Schwenk
Asklepios Klinik Altona

Hamburg, Germany

Prof. Dr. Stefan Seewald
Klinik Hirslanden

Zurich, Switzerland

PD Dr. Uwe Seitz
Kreiskrankenhaus Bergstraße

Heppenheim, Germany

Prof. Dr. Britta Siegmund
Med. Klinik I, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Berlin, Germany

Turn up the volume.

Expand your tissue grasping capabilities with the Instinct Endoscopic Hemoclip. At 16 mm, the jaw span is the widest on the market. And because it is fully adjustable, you can open and close the Instinct clip to securely grasp as much—or as little—tissue as your procedure requires.

For your next clipping procedure, simply follow your instincts to enhanced patient care.

Instinct™
ENDOSCOPIC HEMOCLIP

COOK MEDICAL www.cookmedical.com

Image courtesy of Shou Jiang Tang, MD, University of Mississippi Medical Center, Jackson, MS.

© COOK 2014 ESC-WADV-INSTINCT-EN-201409

Prof. Dr. Julius Spicak
IKEM -Institute for Clinical and Experimental Medicine
Prague, Czech Republic

Dr. Stefan Steurer
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany

Prof. Dr. Andrea Tannapfel
Ruhr-Universität Bochum
Bochum, Germany

Prof. Dr. Katharina Tiemann
MVZ Hanse Histologikum GmbH
Hamburg, Germany

Prof. Dr. Michael Vieth
Klinikum Bayreuth GmbH
Bayreuth, Germany

Prof. Dr. Naohisa Yahagi
Keio University School of Medicine
Tokyo, Japan

Congress Presidents

Prof. Dr. Thomas Rösch
Universitätsklinikum Hamburg-Eppendorf

Prof. Dr. Friedrich Hagenmüller
Asklepios Klinik Altona

PD Dr. Siegbert Faiss
Asklepios Klinik Barmbek

Venue

Congress Center Hamburg - CCH
Marseiller Straße · 20355 Hamburg, Germany

Congress Organization

COCS GmbH – Congress Organisation C. Schäfer
Rosenheimer Str. 145c · 81671 Munich, Germany
Phone: +49 (0)89 – 89 06 77-0
Fax: +49 (0)89 – 89 06 77-77
E-mail: sandra.reber@cocs.de · www.cocs.de

Opening Hours Registration Desk

Thursday, November 5, 2015	4.00 p.m. – 7.00 p.m.
Friday, November 6, 2015	8.00 a.m. – 7.00 p.m.
Saturday, November 7, 2015	8.00 a.m. – 2.00 p.m.

Internet

www.endoclubnord.com

Translation

The conference languages are German and English with translation during the main congress.

Certification

Confirmation of participation will be issued to all participants at the end of the congress. The congress will be certified by the Ärztekammer (General Medical Council) Hamburg.

Liability

The congress organizer will bear no liability for loss, accident, damage or injury to persons or property irrespective of the cause. The client participates at all sessions, tours and events at his/her own risk. Sole place of jurisdiction is Munich, Germany. German law is applicable.

Registration fee

	payment received by Sep 30, 2015	from Oct 1, 2015
Physician	€ 240,-	€ 280,-
Member bng/ESGE	€ 200,-	€ 240,-
Assistance (evidence enclosed)	€ 70,-	€ 90,-
Nurse	€ 70,-	€ 90,-
Student (evidence enclosed)	€ 70,-	€ 90,-
Team Ticket:		
1 physician and 2 nurses	€ 350,-	€ 390,-
1 physician and 3 nurses	€ 400,-	€ 440,-
1 physician and 4 nurses	€ 430,-	€ 470,-

In the registration fee coffee breaks and lunches are included.

Registration

Please register via our website www.endoclubnord.com or complete the enclosed registration form at the end of this program. The final registration date is **November 2, 2015**. After this date on site registration only.

Mode of Payment

On your bank transfer please indicate “ECN 2015” and the name of the participant and transfer funds to the following account:

COCS GmbH, Munich, Germany
HypoVereinsbank Munich, Germany
IBAN: DE30 7002 0270 0039 6131 40
SWIFT/BIC: HYVEDEMMXXX
Please note that we do not cover any bank charges.

Congress Documents

For payments received before October 20, 2015 by participants from Germany, Austria and Switzerland the personal congress documents will be sent by post before the congress. To avoid unnecessary delays the final conference program and your badge holder will be available in the entrance hall of the CCH.

Cancellation

Cancellation in writing must be received no later than October 20, 2015. A service fee of € 20,- will be deducted from the refund amount. Registration fees will not be refunded if cancellations are received at a later date.

Hotel Reservation

Rooms are reserved under www.hrs.de/endoclubnord. Please note that two other big events are taking place in Hamburg at the same time as the ENDOCLUBNORD and hotels will be booked out early.

SMS / E-mails to the moderators

Questions or comments during the sessions can be sent via
SMS: anounced on site
E-mail: ecn@luxav.org

Photography / filming

No photography or filming during lectures or live demonstrations permitted. The organizers will share selected recordings on the website. In case you do not wish to be recorded please advise in advance.

by train

The Congress Center Hamburg is right next door to Dammtor InterCity rail station. For further details related to the exclusive German Railways offer for ENDOCLUBNORD participants please see page 20.

by car

If you come to CCH - Congress Center Hamburg by car or motor bike, please follow the signs to “Messe/CCH” from all directions.

parking

The CCH offers parking for € 2,- per hour and € 14,- per day.

by HVV (public transport)

Dammtor station is right next to CCH, for InterCity trains and S-Bahn. U-Bahn stations Stephansplatz (Opera/CCH) and Gänsemarkt are just a short walk away, on a route that passes through a landscaped park and attractive streets. You will be entitled to use Hamburg‘s entire public transport system for the duration of the conference. The network includes buses, “S-Bahn” (overground trains) and “U-Bahn” (underground metro system) as well as some of the harbour ferries. Your name badge will be valid as your ticket. See map on page 23.

Environment and Climate-Friendly Journey with Deutsche Bahn

Travel by train from Euro 99 with 100% green power to ENDOCLUBNORD

In cooperation with the COCS GmbH and Deutsche Bahn you travel safely and conveniently to ENDOCLUBNORD!

Your way to save the environment: Travel with 100% green power to your event with Deutsche Bahn long-distance services. We guarantee to get the energy you needed for your journey in Germany from 100% renewable sources.

The price for your Event Ticket for a return trip* to Hamburg is:

- 2nd class Euro 99 €
- 1st class Euro 159 €

Our service centre is looking forward to inform you about the ticket price for international journeys. Your ticket is valid from 4th to 9th November 2015.

To book call +49 (0)1806 - 31 11 53** and mention **ENDOCLUBNORD** as reference. Please have your credit card ready when booking. Alternatively, you can also reserve your ticket online at www.bahn.de/Veranstaltungsticket. Your booking will be binding after Deutsche Bahn's confirmation.

Every time you purchase an Event Ticket with your BahnCard or bahn.bonus Card you can col-lect valuable bonus and status points. Redeem your bonus points by selecting attractive rewards such as free journeys or first-class upgrades. For more information go to www.bahn.de/bahn.bonus

Your price advantages compared to the regular prices***:

e. g. for your journey from (return trip)			1st class – 159 €		2nd class – 99 €	
			Regular Fare	Your Price Advantage	Regular Fare	Your Price Advantage
Munich	↔	Hamburg	€460	€301	€284	€185
Frankfurt/M.	↔	Hamburg	€396	€237	€244	€145
Leipzig	↔	Hamburg	€330	€171	€204	€105
Cologne	↔	Hamburg	€314	€155	€194	€95
Berlin	↔	Hamburg	€252	€93	€156	€57

The COCS GmbH and Deutsche Bahn wish you a pleasant journey!

* An advance booking of at least three days is required. Changes and reimbursement before the first day of validity are possible. Changes and reimbursement conditions at the time of the ticket booking are accord-ing to Conditions of Carriage of the DB of Sparpreis fares. Changes and reimbursement are excluded from the first day of validity onwards. Passengers restrict themselves to a particular train and travel times. For a supplement of Euro 40 full flexible tickets are also available for domestic travels within Germany.

** The booking line is available from Monday to Saturday 07:00 am to 10:00 pm. Calls will be charged at Euro 0.20 per call, from mobiles Euro 0.60 per call at maximum.

*** Prices are subject to change.

Special offer: Discounted travel with Lufthansa Group Airlines

Lufthansa Group Partner Airlines offer a comprehensive global route network linking major cities around the world. We offer special prices and conditions to participants, visitors, exhibitors, invited guests as well as employees of the Contracting partner and their travel companions.

To make a reservation, please click on:
www.lufthansa.com/event-booking_en and enter the access code **DEZEDLO** in the „Access to Your Special Lufthansa Offer" area. This will open an online booking platform that will automatically calculate the discount offered or provide you with an even better offer if another promotional fare is available.

Note: Pop-ups must be enabled otherwise the booking platform window will not open.

These promotional fares are also available through your IATA / ARC travel agent. Travel agents can obtain ticketing instructions by sending an email to **lufthansa.mobility@dlh.de** and providing the access code as a reference.

November will be your lucky month:
You`ll meet our innovations.




Discover our latest stent and hemostasis solutions at our booth on „Endo Club Nord 2015“ in November. And in case you don`t want to wait that long: You can get all necessary information on www.micro-tech-europe.com right now.

MT MICRO-TECH



GI Solutions - Advancing the Gastrointestinal Care Continuum

GI solutions brings together three innovative companies – Barrx Medical, Beacon Endoscopic and Given Imaging – to offer gastroenterologists a single-destination diagnostic and therapeutic solution covering the GI care continuum.

Partner with GI Solutions to benefit from improved care and outcomes for your patients, effective diagnostic and treatment options, and an efficient system designed to help lower costs.

One single solution for the continuous care of patients



Screening | Diagnosing | Treating | Monitoring

Barrx™ RFA System
bnx™ FNA System
Bravo® pH Monitoring System
Digitrapper® pH-Z Monitoring System
ManoScan® HRM System
PillCam® Platform
SmartPill® Motility Monitoring System

Discover more at www.covidien.com/gisolutions

[GI Solutions] COVIDIEN *positive results for life*

COVIDIEN, COVIDIEN with logo, Covidien logo and *positive results for life* are U.S. and internationally registered trademarks of Covidien AG. Other brands are trademarks of a Covidien company.
© 2014 Covidien.

Barrett ablation using HybridAPC

One instrument for all Barrett localizations and esophagus lumina

Our benefits
- Waterjet elevation prior to APC ablation
- Thermal protection of the muscularis
- Limited APC penetration depth, minimized risk of stricture
- Targeted, dynamic APC application; healthy epithelium is preserved

Benefits of the HybridAPC probe
- Cost-effective disposable instrument
- With proven APC and waterjet functions
- No instrument change for elevation and ablation





For further information on our complete range of products, visit our home page.

ERBE Elektromedizin GmbH | Tübingen | Telefon +49 7071 755-400 | www.erbe-med.com

ERBE
Perfection for Life

The ENDOCLUBNORD is grateful for the support of its sponsors:

- Olympus Deutschland GmbH, Hamburg
- AbbVie Deutschland GmbH & Co. KG, Wiesbaden
- Cook Deutschland GmbH, Mönchengladbach
- Covidien Deutschland GmbH, Hamburg
- Erbe Elektromedizin GmbH, Tübingen
- Dr. Falk Pharma GmbH, Freiburg
- marpinion Market Research GmbH, Oberhaching
- Micro-Tech Europe GmbH, Düsseldorf
- Norgine GmbH, Marburg
- NPS Pharma Germany GmbH, Frankfurt am Main
- Recordati Pharma GmbH, Ulm
- Takeda Pharma Vertrieb GmbH & Co. KG, Berlin

Without engagement - status print date

Next-Generation Communication with Physicians

HELP MAKE A DIFFERENCE BY BECOMING AN OPINION LEADER!

marpinion®: the new approach to communicating with physicians.

Come see us at Endo Club Nord 2015 – your personal iPad is waiting for you! We'll demonstrate our innovative new app and show how you too can benefit from marpinion®. If you like, we'll also be happy to visit you in your practice with no further obligation on your part. Just give us a ring!

marpinion®

marpinion Market Research GmbH | Raiffeisenallee 16 | 82041 Oberhaching | Phone +49 89 1 222 836-800 | www.marpinion.de | info@marpinion.de

REGISTRATION

Please cut off and send in a window envelope.

Registration also at:
www.endoclubnord.com

I will participate at the ENDOCLUBNORD 2015

	payment received by Sep 30, 2015	from Oct 1, 2015
☐ Physician	€ 240,-	€ 280,-
☐ Member of bng	€ 200,-	€ 240,-
☐ Member of ESGE	€ 200,-	€ 240,-
☐ Assistance (evidence enclosed)	€ 70,-	€ 90,-
☐ Nurse	€ 70,-	€ 90,-
☐ Student (evidence enclosed)	€ 70,-	€ 90,-
Team-Ticket		
☐ 1 physician and 2 nurses	€ 350,-	€ 390,-
☐ 1 physician and 3 nurses	€ 400,-	€ 440,-
☐ 1 physician and 4 nurses	€ 430,-	€ 470,-

Name of the nurses attending (last name, first name):

1. _____
2. _____
3. _____
4. _____

NEW: Workshops on Friday

I take part on Friday, November 6, 2015, 05.15 p.m. to 06.30 p.m:

- ☐ Seminar für Pflege- und Assistenzpersonal
- ☐ Workshop 1 - Advanced polypectomy
- ☐ Workshop 2 - ERCP – Cannulation, precut and sphincterotomy
- ☐ Workshop 3 - Early tumors in esophagus and stomach
- ☐ Workshop 4 - Overview on Novel Pancreatibiliary Interventions

Please deposit the total amount to the account indicated below:
COCS GmbH, Munich, Germany
HypoVereinsbank München
IBAN: DE30 7002 0270 0039 6131 40 · SWIFT/BIC: HYVEDEMMXXX
Keyword: ECN2015 and name of participant
Please note that we do not cover any bank charges.

Date, Signature

REGISTRATION

Register by post or online: www.endoclubnord.com

COCS GmbH
Congress Organisation C. Schaefer
Rosenheimer Str. 145c
81671 Munich
Germany

☐ Ms. ☐ Mr. ☐ Prof. ☐ PD Dr. ☐ Dr.

Last Name

First Name

Hospital/Institute/Practice

Department

Street

Zip Code City

Area Code Phone

E-mail

Statistics: ☐ Office-based physician ☐ Hospital-based physician

Specialisation: ☐ Gastroenterology ☐ Surgery ☐ Internal medicine ☐ Others

Ulcerative Colitis and Crohn's Disease:

TREAT WITH PRECISION AT THE SITE OF INFLAMMATION

GUT-SELECTIVE

- Lasting remission[1–3]
- Good tolerability profile[1–3]
- The first ever gut-selective integrin receptor antagonist for moderately to severely active ulcerative colitis and Crohn's disease[1–4]

Approved for use in patients following **conventional therapy** or anti-TNF therapy[1]

1. Entyvio® Summary of Product Characteristics. 05/2014. 2. Feagan BG, et al. N Engl J Med. 2013; 369(8): 699–710. 3. Sandborn WJ, et al. N Engl J Med. 2013; 369(8): 711–721. 4. Wyant T, et al. Gut. 2014; 0:1–7. doi: 10.1136/gutjnl-2014-307127

Entyvio® 300 mg powder for concentrate for solution for infusion

Active substance: vedolizumab. Description: *Active ingredient:* Each vial contains 300 mg of vedolizumab after reconstitution, each mL solution for infusion contains 60 mg vedolizumab. *Excipients:* L-histidine, L-histidine monohydrochloride, L-arginine hydrochloride, sucrose, polysorbate 80. Therapeutic indications and posology: *Ulcerative colitis:* Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. *Crohn's disease:* Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. Contraindications: Hypersensitivity to the active substance or to any of its excipients. Active severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML), (see SmPC section 4.4). Adverse reactions: *Very common:* nasopharyngitis, headache, arthralgia; *common:* bronchitis, gastroenteritis, upper respiratory tract infection, influenza, sinusitis, pharyngitis, paresthesia, hypertension, oropharyngeal pain, nasal congestion, cough, anal abscess, anal fissure, nausea, dyspepsia, constipation, abdominal distension, flatulence, haemorrhoids, rash, pruritus, eczema, erythema, night sweats, acne, muscle spasms, back pain, muscular weakness, fatigue, pyrexia; *Uncommon:* respiratory tract infections, vulvovaginal candidiasis, oral candidiasis, folliculitis, infusion site reaction (incl. infusion site pain and infusion site irritation), infusion related reaction chills, shivering, feeling cold. During the second infusion, one case of a serious infusion related reaction was reported by a Crohn's disease patient during the second infusion (symptoms reported were dyspnea, bronchospasm, urticaria, flushing, rash, as well as, increased blood pressure and heart rate) and was managed with discontinuation of infusion and treatment with antihistamine and intravenous hydrocortisone. *Infections:* In controlled and open-label long-term extension studies in adults with vedolizumab, serious infections have been reported, which include tuberculosis, sepsis (some fatal), salmonella sepsis, listeria meningitis, and cytomegalovirus colitis. *Malignancy:* Overall, results from the clinical program to date do not suggest an increased risk for malignancy with vedolizumab treatment.; However, the number of malignancies in the clinical trials was small, long-term exposure was limited. Long-term safety evaluations are ongoing. For drug interactions and other information, see SmPC. Prescription only. EU marketing authorisation holder: Takeda Pharma A/S, Taastrup, Danemark. Contact address of the pharmaceutical company in Germany: Takeda GmbH, Byk-Gulden-Straße 2, 78467 Konstanz, Tel.: 0800 825 3325, medinfo@takeda.de. 05/2014

Takeda

Entyvio® Vedolizumab

© 2014 Takeda Pharma Vertrieb, GmbH & Co. KG